Article
GSK begins patient dosing in phase 3 trial of RSV maternal candidate
Rating:
0.0
Views:
103
Likes:
1
Library:
1
GSK has started patient dosing in a phase 3 clinical trial to assess the safety and efficacy of the respiratory syncytial viirus (RSV) vaccine candidate
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value